(1 - 16 von 18
)
The Conspiracy To End Cancer | TIME.com
healthland.time.com
The hero scientist who defeats cancer will likely never exist. No exalted individual, no victory celebration, no Marie Curie or Jonas Salk, who in 1955, after...
Patients clamor to get into trials for immunotherapy, the new...
www.chron.com
Campbell, a retired engineer and former Navy captain, had harbored no illusions that...
Visiting Speakers Program in Oncology - Dr. John Heymach "Molecular...
www.mcgill.ca
Assistant Professor, Thoracic, Head and Neck Department, University of Texas, M.D. Anderson Cancer Center, Houston, TX
M.D. Anderson launches $3 billion fight against common cancers
www.chron.com
The University of Texas M.D. Anderson Cancer Center on Friday will announce an ambitious...
Visiting Speakers Program in Oncology - Dr. John Heymach...
www.mcgill.ca
Dr. David Miles trained at University College London with postgraduate training at Kings College, University College and Guys Hospital. In 2004, he was...
New blood test key to future of cancer treatment
www.chron.com
A new cancer test that performs a liquid biopsy in patients garnered widespread headlines...
Immatics Initiates the First Phase I Clinical Trial of its Unique...
www.bioregio-stern.de
Immatics Initiates the First Phase I Clinical Trial of its Unique ACTengine® Approach in Patients with Advanced Solid Cancers ... M.D., in the Department of Thoracic Oncology at MD Anderson (Department Chair: Professor John Heymach, M.D., Ph.D.) is the ...
Ca al polmone con EGFR mutato, dacomitinib vince su gefitinib nel
www.pharmastar.it
L inibitore dell EGFR di seconda generazione dacomitinib ha prolungato in modo significativo la sopravvivenza libera da progressione PFS , ridotto il rischio...
AACR 2015: New Subsets of Lung Cancer With KRAS Gene Mutations...
ascopost.com
... heterogeneity of KRAS-mutant tumors,” said John Heymach, MD, ... R01 CA A1, CA , and 1R01 CAQ ), The V ...
MD Anderson and Bristol-Myers Squibb Announce New Research...
www.newswise.com
Bristol-Myers Squibb Company and The University of Texas MD Anderson Cancer Center today announced a new clinical research collaboration to evaluate innovative
Rival drug firms team up to test new cancer treatment approach
www.statnews.com
Rival biotech and pharma heavyweights are teaming up to accelerate testing of a new cancer treatment field.
Bevacizumab may prolong PFS after progression of advanced NSCLC
www.healio.com
John Heymach. John V. Heymach. However, little research has been conducted on the efficacy of bevacizumab beyond disease progression in ...
Bristol Myers Squibb - Bristol-Myers Squibb and MD Anderson Announce...
news.bms.com
... standard of care and expanding treatment options for all patients, including those with early stage disease,” said John Heymach, M.D., Ph.D., ...
Cancer Stem Cells Linked to Drug Resistance
health.ucsd.edu
Most drugs used to treat lung, breast and pancreatic cancers also promote drug-resistance and ultimately spur tumor growth. Researchers at the University of...
New subsets of lung cancer with KRAS gene mut | EurekAlert!
www.eurekalert.org
Mutations of the KRAS gene are commonly known to lead to cancer. However, deeper understanding of exactly how they do this continues to be explored by cancer...
First Precision Medicine Trial in Cancer Prevention Identifies...
health.ucsd.edu
A team of scientists, led by researchers at University of California, San Diego Moores Cancer Center and The University of Texas MD Anderson Cancer Center,...
sortiert nach Relevanz / Datum